Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

able, less current portion - 119,000

Capital lease obligation, less current portion 17,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock-$.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock-$.001 par value; authorized

325,000,000 shares; outstanding -

226,210,617 and 196,112,201, respectively 226,000 196,000

Additional paid-in capital 245,982,000 224,453,000

Accumulated deficit (224,677,000) (207,660,000)

Total stockholders' equity 21,531,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $28,241,000 $22,997,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED NINE MONTHS ENDED

January 31, January 31, January 31 January 31,

2008 2007 2008 2007

Unaudited Unaudited Unaudited Unaudited

REVENUES:

Contract

manufacturing

revenue $1,662,000 $347,000 $5,146,000 $1,381,000

License revenue 13,000 16,000 46,000 87,000

Total revenues 1,675,000 363,000 5,192,000 1,468,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 1,289,000 223,000 3,872,000 1,247,000

Research and

development 4,941,000 3,907,000 13,665,000 11,868,000

Selling, general

and administrative 1,847,000 1,513,000 5,498,000 4,824,000

Total costs

and expenses
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... , July 10, 2014 Research and ... of the "International Photonic Integrated Circuit (Monolithic ... to 2019" report to their offering. ... The concept of photonic integration traces its roots ... The promise of photonic integration went unexplored and ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... body of an ordinary family car consists of 193 different ... car has been carefully selected and optimised. It is important, ... because of the fuel consumption, whereas other parts of the ... passengers in a collision. Super strong nanostructured metals ...
... 21, 2011 ViroPharma Incorporated,s (Nasdaq: VPHM ) ... released on Thursday, July 28, 2011 before the open of ... a conference call and live audio webcast at 9:00 a.m. ... ViroPharma management will discuss the 2011 second quarter financial results ...
... Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer ... Merrill A. McPeak to its Board of Directors.  General ... Force and was USAF chief of staff from 1990 ... 7 members, including 5 independent directors. "General ...
Cached Biology Technology:A new discovery paves the way for using super strong nanostructured metals in cars 2A new discovery paves the way for using super strong nanostructured metals in cars 3ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011 2Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors 2
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... in eastern New South Wales, Australia when NASA,s Aqua ... UTC on July 11 (12:35 p.m. local time/11:35 p.m. ... New South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer ... region and spotted smoke (light brown) from various fires. ... outlined in red. , The New South Wales, Australia ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... researchers have discovered that a recently identified protein critical ... keep its repairs accurate. , The protein, called ... proteins known as DNA polymerases that are vital for ... other DNA-repair proteins insure their accuracy with the help ...
... sheds light on the molecular mechanisms underlying axon growth ... a study published today in the open access journal ... UNC-69, required for proper locomotion . They show that ... to be involved in the trafficking of vesicles along ...
... Portabella and crimini mushrooms rank with carrots, green beans, ... antioxidants, Penn State researchers say. , Dr. N. Joy ... at Penn State, measured the activity of two antioxidants, ... assay and HPLC instrumentation, as part of her dissertation ...
Cached Biology News:Unusual mechanism keeps repair protein accurate 2Unusual mechanism keeps repair protein accurate 3Newly identified protein complex sheds light on axon growth mechanism 2Mushrooms as good an antioxidant source as more colorful veggies 2
... scientists developed the Easy-Titer Human IgM Assay ... simple, sensitive, and easy-to-perform assay for Human ... ELISA. This kit incorporates a simple mix-and-read ... IgM concentration from 15-500 ng/ml in approximately ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... true benchtop incubator-shaker, has the smallest footprint of ... of 540 x 680 mm (W x D) ... x 505 x 510mm). Available in 25 mm ... ideal for shaking applications requiring controlled speed and ...
Biology Products: